Molecular-targeted therapies in head and neck cancer Journal Article

  


Authors: Rao, S. D.; Fury, M. G.; Pfister, D. G.
Article Title: Molecular-targeted therapies in head and neck cancer
Abstract: The increasing understanding of tumor biology has opened the door to a new class of biological agents directed at specific molecular targets in the treatment of squamous cell carcinomas of the head and neck. These targeted agents present the opportunity to more effectively attack the crucial cellular pathways contributing to tumor growth and survival, while minimizing toxicity. Cetuximab, which targets epidermal growth factor (EGF) receptor signaling, was the first such biological agent to be proven effective in head and neck squamous cell cancers. Currently, there are dozens of targeted agents at various stages of testing for use in the treatment of head and neck cancers. In this article, we review strategies aimed at key pathways, including EGF receptor signaling, the Vascular Endothelial Growth Factor (VEGF) pathway, and PI3K/AKT/mammalian target of rapamycin activation. © 2012.
Keywords: immunohistochemistry; signal transduction; cancer survival; vascular endothelial growth factor a; survival rate; unclassified drug; gene mutation; overall survival; review; carcinoma, squamous cell; fistula; sorafenib; bevacizumab; cisplatin; erlotinib; fluorouracil; sunitinib; cancer combination chemotherapy; drug efficacy; monotherapy; antineoplastic agents; radiation dose; drug megadose; colorectal cancer; cell proliferation; cell survival; carboplatin; progression free survival; apoptosis; bleeding; mucosa inflammation; lung cancer; receptor, epidermal growth factor; enzyme activation; dasatinib; angiogenesis; autophosphorylation; cetuximab; kidney carcinoma; panitumumab; temsirolimus; loading drug dose; drug fatality; survival time; antibodies, monoclonal; add on therapy; head and neck cancer; head and neck neoplasms; pancreas tumor; gefitinib; cediranib; pazopanib; vandetanib; upregulation; kidney cancer; nasopharynx cancer; pemetrexed; everolimus; cell invasion; ligand binding; lapatinib; perifosine; skin ulcer; zalutumumab; head and neck squamous cell carcinoma; saracatinib; molecularly targeted therapy; figitumumab; molecular targeted therapy; nimotuzumab; tor serine-threonine kinases; afatinib; dacomitinib; cp 75187; krx 040; xl 147
Journal Title: Seminars in Radiation Oncology
Volume: 22
Issue: 3
ISSN: 1053-4296
Publisher: Elsevier Inc.  
Date Published: 2012-07-01
Start Page: 207
End Page: 213
Language: English
DOI: 10.1016/j.semradonc.2012.03.005
PROVIDER: scopus
PUBMED: 22687945
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84862126545&partnerID=40&md5=d175e2e16adf078f96fe6768b12ac837
Notes: --- - "Export Date: 2 July 2012" - "CODEN: SRONE" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. David G Pfister
    389 Pfister
  2. Matthew G Fury
    102 Fury
  3. Shyam S Rao
    83 Rao
Related MSK Work